"This is to establish a 'One Team' system that can respond immediately and flexibly to any crisis or change," said Hwang Sang-yeon, the first external CEO of Hana Pharm since its founding in 1973, as he initiated a major restructuring. This decision aims to effectively achieve business goals in response to the rapidly changing global pharmaceutical and biotech market by integrating existing divisions based on work relevance into a new 'departmental system.'
According to Hana Pharm, the company was reorganized on May 1 into four core integrated areas: innovation growth, sustainable growth, future growth, and growth support.
A key aspect of this restructuring is the establishment of the 'Innovation Growth Division.' To ensure the successful domestic and international launch of its obesity treatment, Hana Pharm plans to maximize synergy by consolidating its new product development center, marketing center, Pyeongtaek manufacturing center, pharmaceutical innovation center, and overseas sales team.
The existing R&D center has been restructured into the 'Future Growth Division,' which will house three centers: the Obesity Metabolism Center, the Oncology Center, and the Convergence Center, ensuring research and development independence while continuously discovering innovative early-stage pipelines.
Additionally, the domestic sales headquarters has been elevated to the 'Sustainable Growth Division' to enhance its external standing, while the 'Growth Support Division' will include the Paltan manufacturing center and business management center to support the efficient operation of each growth area.
The 'Portfolio Committee' has been restructured to include the clinical center, serving as a control tower to make final decisions on the company's overall portfolio, including new projects and product adjustments.
On May 6, Hwang held a town hall meeting at Hana Pharm's headquarters in Songpa-gu, Seoul, to explain the purpose and details of the restructuring to employees.
He emphasized that this restructuring is not merely a "game of musical chairs" with department names, but rather a move to create a 'One Team' system that can respond immediately and flexibly to any crisis or change, akin to a snake shedding its skin.
Hwang further stated, "We focused on breaking down barriers between departments and concentrating the company's capabilities solely on achieving business objectives. We aim to establish an integrated system where each division is organically connected, transforming into a global pharmaceutical and biotech company that simultaneously realizes innovative drug development and sustainable growth."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.